Q1 2024 presentation and Q&A
Agenda
- Medical cannabis market in Europe
- Introduction to Stenocare, which provides medical cannabis in five countries
- Key messages from Stenocare's Q1 2023 report
How does this Q&A work:
This company invites all interested, both current investors and potential investors to participate in this event, ask questions directly on this page before the event starts and upvote those questions you would like addressed.
The company will address as many questions as possible, and focus on those questions most wanted by investors.
Speakers at this event:
10 Questions
April 22, 2024
Why is the loss increasing all the time when you should be getting closer to break even?
May 2, 2024
What is the status of your own facility? We have not heard anything since you began operations back in 2018-2019. Why have licenses not been obtained (GACP, EU-GMP, etc.)? Many others in the industry (DK, etc.) have obtained these in far less time, both indoor and hybrid.
And why do you believe you can compete with other countries where the coverage will not be comparable to an expensive product from Denmark (in terms of cultivation)?
May 2, 2024
Can you explain the seasonality in your sales and also at the same time put some more information on your guidance. You have only reached less than 10% of your gross sales outlook target in Q1, when do you expect to see significant ramp up in this number to reach full year outlook?
April 29, 2024
What are your thoughts on the following questions:
1. How do you address the increasing competition both nationally and internationally for a generic product like yours, and the increasingly lower margins associated with it?
2. How do you approach your product range, which currently consists solely of extracts? Do you have ambitions to explore other delivery formats?
3. How do you view consolidation within the industry, and is it something you are considering?
May 2, 2024
How do you tackle the issue regarding the reimbursement issue in the DK market (especially compared to the magistral cannabis medicines)?
May 2, 2024
Can you educate us in terms of the sales numbers in the different contries (percentages)?
May 2, 2024
Germany just legalized cannabis in April, the US “Drug Enforcement Administration” (DEA) has announced plans to declassify cannabis and even Berlingske Tidende has a large story yesterday about legalization of cannabis. What is your analysis and expectation for impact on the Stenocare business?
May 2, 2024
What is the advantage of your new product that combines THC and CBD in one product?
April 23, 2024
The price of Stenocare products is quite high, do you have a strategy for getting pricing down to be usefull for a broader market or how do you see your pricing stratgy?
April 23, 2024
What do you expect from the newly released product with a combination of CBD and THC? How is demand compared to your other two products?